Combination treatment for HER2-positive advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your stomach or gastroesophageal junction cancer cannot be removed by surgery, either because it has spread locally or to other parts of the body.
- Your tumor has tested positive for a protein called HER2 at levels 2+ or 3+.
- You haven't had systemic treatment for advanced disease, or if you had adjuvant/neoadjuvant treatment, it was more than 6 months ago.
- You have reasonably good physical function (able to care for yourself) and adequate organ function (bone marrow, liver, kidneys, heart).
- You do not have severe heart conditions, history of certain lung diseases, active infections, or brain metastasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a combination of two targeted drugs (disitamab vedotin and sintilimab) along with radiation for HER2-positive stomach cancer that has stopped responding to standard treatments. The goal is to see if this combo can shrink tumors and help you live longer.
This trial tests a combination of three drugs—disitamab vedotin, tunlametinib, and a PD-1 antibody—for people with advanced stomach cancer that has HER2 (a protein that helps cancer grow). The goal is to see if this combo can shrink tumors or slow the cancer, and whether it's safe.
Hear when a new HER2-positive Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.